IMUGENE LIMITED — Capital/Financing Update 2013

Apr 29, 2013

==> picture [227 x 48] intentionally omitted <==

Share

Purchase Plan – Cleansing Notice

30 April 2013

In accordance with ASIC Class Order 09/425 ( CO 09/425 ), Imugene Limited (ASX: IMU) (the Company ) gives notice that:

• a) the Company will make offers to issue ordinary shares under a Share Purchase Plan ( SPP ) without disclosure under Part 6D.2 of the Corporations Act 2001 (Cth) ( Act );

• b) this notice is given in accordance with CO 09/425 and in particular, paragraph 7(f)(ii) of CO 09/425 which requires that the Company give this notice to ASX within the 24 hour period before the SPP offer;

• c) as at the date of this notice, the Company has complied with:

  1. the provisions of Chapter 2M of the Act as they apply to the Company; and 2. section 674 of the Act; and

• d) as at the date of this notice, the Company confirms that there is no information that is ‘excluded information’ (as defined in subsections 708A(7) and 708A(8) of the Act) which is required to be disclosed by the Company.

==> picture [55 x 57] intentionally omitted <==

Justyn Stedwell Company Secretary On behalf of the Board of Directors Imugene Limited

About Imugene

Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) Linguet™ technology. Linguet™ is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products.